Advertisement
08-03-2025 | Gastric Cancer | REVIEW
Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
Published in: Current Treatment Options in Oncology
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/s0140-6736(20)31288-5.CrossRefPubMed
Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635–48. https://doi.org/10.1016/s0140-6736(20)31288-5.CrossRefPubMed
2.
go back to reference Guan WL, et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https://doi.org/10.1186/s13045-023-01451-3.CrossRefPubMedPubMedCentral
Guan WL, et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https://doi.org/10.1186/s13045-023-01451-3.CrossRefPubMedPubMedCentral
3.
go back to reference Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x.CrossRefPubMed
Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x.CrossRefPubMed
4.
go back to reference Ajani JA, et al. Gastric Cancer, Version 22022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008.CrossRefPubMed
Ajani JA, et al. Gastric Cancer, Version 22022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167–92. https://doi.org/10.6004/jnccn.2022.0008.CrossRefPubMed
5.
go back to reference Blangé D, et al. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review. Cancer Treat Rev. 2022;108:102418. https://doi.org/10.1016/j.ctrv.2022.102418.CrossRefPubMed
Blangé D, et al. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review. Cancer Treat Rev. 2022;108:102418. https://doi.org/10.1016/j.ctrv.2022.102418.CrossRefPubMed
6.
go back to reference Shitara K, et al. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia Pac J Clin Oncol. 2019;16(1):5–13. https://doi.org/10.1111/ajco.13243.CrossRefPubMed
Shitara K, et al. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia Pac J Clin Oncol. 2019;16(1):5–13. https://doi.org/10.1111/ajco.13243.CrossRefPubMed
7.
go back to reference Ruschoff J, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50. https://doi.org/10.1038/modpathol.2011.198.CrossRefPubMed
Ruschoff J, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50. https://doi.org/10.1038/modpathol.2011.198.CrossRefPubMed
8.
go back to reference Tokunaga M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024;27(3):580–9. https://doi.org/10.1007/s10120-024-01467-9.CrossRefPubMed
Tokunaga M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Gastric Cancer. 2024;27(3):580–9. https://doi.org/10.1007/s10120-024-01467-9.CrossRefPubMed
9.
go back to reference Hofheinz RD, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322–31. https://doi.org/10.1002/ijc.33696.CrossRefPubMed
Hofheinz RD, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322–31. https://doi.org/10.1002/ijc.33696.CrossRefPubMed
10.
go back to reference Rivera F, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158–67. https://doi.org/10.1016/j.ejca.2020.12.005.CrossRefPubMed
Rivera F, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158–67. https://doi.org/10.1016/j.ejca.2020.12.005.CrossRefPubMed
11.
go back to reference Janjigian YY, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/s1470-2045(20)30169-8.CrossRefPubMedPubMedCentral
Janjigian YY, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31. https://doi.org/10.1016/s1470-2045(20)30169-8.CrossRefPubMedPubMedCentral
12.
go back to reference Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.CrossRefPubMedPubMedCentral
Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.CrossRefPubMedPubMedCentral
13.
go back to reference Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208. https://doi.org/10.1016/s0140-6736(23)02033-0.CrossRefPubMed
Janjigian YY, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197–208. https://doi.org/10.1016/s0140-6736(23)02033-0.CrossRefPubMed
14.
go back to reference Lee CK, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun. 2022;13(1):6002. https://doi.org/10.1038/s41467-022-33267-z.CrossRefPubMedPubMedCentral
Lee CK, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun. 2022;13(1):6002. https://doi.org/10.1038/s41467-022-33267-z.CrossRefPubMedPubMedCentral
15.
go back to reference Montagnani F, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14(1):50–5. https://doi.org/10.1007/s10120-011-0007-7.CrossRefPubMed
Montagnani F, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14(1):50–5. https://doi.org/10.1007/s10120-011-0007-7.CrossRefPubMed
16.
go back to reference Kim GM, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518–26. https://doi.org/10.1016/j.ejca.2011.12.017.CrossRefPubMed
Kim GM, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 2012;48(4):518–26. https://doi.org/10.1016/j.ejca.2011.12.017.CrossRefPubMed
17.
go back to reference Mori Y, et al. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer. 2022;53(4):930–8. https://doi.org/10.1007/s12029-021-00711-0.CrossRefPubMed
Mori Y, et al. Phase II Prospective Study of Trastuzumab in Combination with S-1 and Oxaliplatin (SOX100) Therapy for HER2-Positive Advanced Gastric Cancer. J Gastrointest Cancer. 2022;53(4):930–8. https://doi.org/10.1007/s12029-021-00711-0.CrossRefPubMed
18.
go back to reference Takahari D, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238–46. https://doi.org/10.1007/s10120-019-00973-5.CrossRefPubMed
Takahari D, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238–46. https://doi.org/10.1007/s10120-019-00973-5.CrossRefPubMed
19.
go back to reference Yuki S, et al. Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemother Pharmacol. 2020;85(1):217–23. https://doi.org/10.1007/s00280-019-03991-3.CrossRefPubMed
Yuki S, et al. Multicenter phase II study of SOX plus trastuzumab for patients with HER2(+) metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemother Pharmacol. 2020;85(1):217–23. https://doi.org/10.1007/s00280-019-03991-3.CrossRefPubMed
20.
go back to reference Makiyama A, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/jco.19.03077.CrossRefPubMed
Makiyama A, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/jco.19.03077.CrossRefPubMed
21.
go back to reference Horita Y, et al. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. Anticancer Drugs. 2019;30(1):98–104. https://doi.org/10.1097/cad.0000000000000691.CrossRefPubMed
Horita Y, et al. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer. Anticancer Drugs. 2019;30(1):98–104. https://doi.org/10.1097/cad.0000000000000691.CrossRefPubMed
22.
go back to reference Kawamoto Y, et al. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist. 2022;27(5):340-e374. https://doi.org/10.1093/oncolo/oyab062.CrossRefPubMedPubMedCentral
Kawamoto Y, et al. Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). Oncologist. 2022;27(5):340-e374. https://doi.org/10.1093/oncolo/oyab062.CrossRefPubMedPubMedCentral
23.
go back to reference Takahashi M, et al. Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203). Tohoku J Exp Med. 2021;254(1):49–55. https://doi.org/10.1620/tjem.254.49.CrossRefPubMed
Takahashi M, et al. Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203). Tohoku J Exp Med. 2021;254(1):49–55. https://doi.org/10.1620/tjem.254.49.CrossRefPubMed
24.
go back to reference Sun J, et al. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. J Inflamm Res. 2022;15:4061–85. https://doi.org/10.2147/jir.S368138.CrossRefPubMedPubMedCentral
Sun J, et al. From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. J Inflamm Res. 2022;15:4061–85. https://doi.org/10.2147/jir.S368138.CrossRefPubMedPubMedCentral
25.
go back to reference Zhang H, et al. Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. Sci Rep. 2022;12(1):10461. https://doi.org/10.1038/s41598-022-14336-1.CrossRefPubMedPubMedCentral
Zhang H, et al. Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo. Sci Rep. 2022;12(1):10461. https://doi.org/10.1038/s41598-022-14336-1.CrossRefPubMedPubMedCentral
26.
go back to reference Song Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867–78. https://doi.org/10.1007/s13238-017-0384-8.CrossRefPubMed
Song Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867–78. https://doi.org/10.1007/s13238-017-0384-8.CrossRefPubMed
27.
go back to reference Luo F, et al. Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 2016;26(7):850–3. https://doi.org/10.1038/cr.2016.81.CrossRefPubMedPubMedCentral
Luo F, et al. Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer. Cell Res. 2016;26(7):850–3. https://doi.org/10.1038/cr.2016.81.CrossRefPubMedPubMedCentral
28.
go back to reference Dong X, et al. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023;129(3):551–62. https://doi.org/10.1038/s41416-023-02319-6.CrossRefPubMedPubMedCentral
Dong X, et al. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023;129(3):551–62. https://doi.org/10.1038/s41416-023-02319-6.CrossRefPubMedPubMedCentral
29.
go back to reference Sheikhlary S, et al. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. Biomolecules. 2024;14(4). https://doi.org/10.3390/biom14040503.
Sheikhlary S, et al. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review. Biomolecules. 2024;14(4). https://doi.org/10.3390/biom14040503.
30.
go back to reference Wiedermann U, et al. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. Clin Cancer Res. 2021;27(13):3649-3660. https://doi.org/10.1158/1078-0432.Ccr-20-3742.
Wiedermann U, et al. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001. Clin Cancer Res. 2021;27(13):3649-3660. https://doi.org/10.1158/1078-0432.Ccr-20-3742.
31.
go back to reference Ede NJ, et al. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. Front Oncol. 2022;12:939356. https://doi.org/10.3389/fonc.2022.939356.CrossRefPubMedPubMedCentral
Ede NJ, et al. Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. Front Oncol. 2022;12:939356. https://doi.org/10.3389/fonc.2022.939356.CrossRefPubMedPubMedCentral
32.
go back to reference Hu HH, et al. HER2(+) advanced gastric cancer: Current state and opportunities (Review). Int J Oncol. 2024;64(4). https://doi.org/10.3892/ijo.2024.5624.
Hu HH, et al. HER2(+) advanced gastric cancer: Current state and opportunities (Review). Int J Oncol. 2024;64(4). https://doi.org/10.3892/ijo.2024.5624.
33.
go back to reference Jung M, et al. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer. Cancer Res Treat. 2024;56(1):208–18. https://doi.org/10.4143/crt.2022.1328.CrossRefPubMed
Jung M, et al. First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer. Cancer Res Treat. 2024;56(1):208–18. https://doi.org/10.4143/crt.2022.1328.CrossRefPubMed
34.
go back to reference Wiedermann U, et al. A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. 2019;37(4_suppl):p. TPS176-TPS176. https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS176.
Wiedermann U, et al. A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. 2019;37(4_suppl):p. TPS176-TPS176. https://doi.org/10.1200/JCO.2019.37.4_suppl.TPS176.
35.
go back to reference Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. 2020;38(15_suppl):3110-3110. https://doi.org/10.1200/JCO.2020.38.15_suppl.3110.
Metz H, et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. 2020;38(15_suppl):3110-3110. https://doi.org/10.1200/JCO.2020.38.15_suppl.3110.
36.
go back to reference Li BT, et al. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. 2023;41(16_suppl):2538-2538. https://doi.org/10.1200/JCO.2023.41.16_suppl.2538.
Li BT, et al. A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. 2023;41(16_suppl):2538-2538. https://doi.org/10.1200/JCO.2023.41.16_suppl.2538.
37.
go back to reference Shen A, et al. A novel 4–1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023;13(7):3246–56.PubMedPubMedCentral
Shen A, et al. A novel 4–1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells. Am J Cancer Res. 2023;13(7):3246–56.PubMedPubMedCentral
38.
go back to reference Sun W, et al. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J Immunother Cancer. 2022;10(7). https://doi.org/10.1136/jitc-2022-005063.
Sun W, et al. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer. J Immunother Cancer. 2022;10(7). https://doi.org/10.1136/jitc-2022-005063.
39.
go back to reference Tateyama N, et al. Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. Pharmaceutics. 2022;14(11). https://doi.org/10.3390/pharmaceutics14112494.
Tateyama N, et al. Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma. Pharmaceutics. 2022;14(11). https://doi.org/10.3390/pharmaceutics14112494.
40.
go back to reference Oberg HH, et al. Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Front Immunol. 2018;9:814. https://doi.org/10.3389/fimmu.2018.00814.CrossRefPubMedPubMedCentral
Oberg HH, et al. Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. Front Immunol. 2018;9:814. https://doi.org/10.3389/fimmu.2018.00814.CrossRefPubMedPubMedCentral
41.
go back to reference Yu S, et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019;38(1):355. https://doi.org/10.1186/s13046-019-1354-1.CrossRefPubMedPubMedCentral
Yu S, et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019;38(1):355. https://doi.org/10.1186/s13046-019-1354-1.CrossRefPubMedPubMedCentral
42.
go back to reference Lin W, et al. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis. Adv Sci (Weinh). 2023;10(30):e2303908. https://doi.org/10.1002/advs.202303908.CrossRefPubMed
Lin W, et al. Anti-PD-1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2-Positive Gastric Cancer through Gasdermin B-Cleavage Induced Pyroptosis. Adv Sci (Weinh). 2023;10(30):e2303908. https://doi.org/10.1002/advs.202303908.CrossRefPubMed
43.
go back to reference Chau CH, et al. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804. https://doi.org/10.1016/s0140-6736(19)31774-x.CrossRefPubMed
Chau CH, et al. Antibody-drug conjugates for cancer. Lancet. 2019;394(10200):793–804. https://doi.org/10.1016/s0140-6736(19)31774-x.CrossRefPubMed
44.
go back to reference Shin SH, et al. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh). 2021;8(23):e2102414. https://doi.org/10.1002/advs.202102414.CrossRefPubMed
Shin SH, et al. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh). 2021;8(23):e2102414. https://doi.org/10.1002/advs.202102414.CrossRefPubMed
45.
go back to reference Lordick F, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.CrossRefPubMed
Lordick F, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.CrossRefPubMed
46.
go back to reference Van Cutsem E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744–56. https://doi.org/10.1016/s1470-2045(23)00215-2.CrossRefPubMedPubMedCentral
Van Cutsem E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744–56. https://doi.org/10.1016/s1470-2045(23)00215-2.CrossRefPubMedPubMedCentral
47.
go back to reference Shitara K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.CrossRefPubMed
Shitara K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.CrossRefPubMed
48.
go back to reference Meric-Bernstam F, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47–58. https://doi.org/10.1200/jco.23.02005.CrossRefPubMed
Meric-Bernstam F, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42(1):47–58. https://doi.org/10.1200/jco.23.02005.CrossRefPubMed
49.
go back to reference Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90. https://doi.org/10.1158/0008-5472.Can-08-1776.CrossRefPubMed
Lewis Phillips GD, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90. https://doi.org/10.1158/0008-5472.Can-08-1776.CrossRefPubMed
50.
go back to reference Thuss-Patience PC, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–53. https://doi.org/10.1016/s1470-2045(17)30111-0.CrossRefPubMed
Thuss-Patience PC, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–53. https://doi.org/10.1016/s1470-2045(17)30111-0.CrossRefPubMed
51.
go back to reference Wang H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108(7):1458–68. https://doi.org/10.1111/cas.13253.CrossRefPubMedPubMedCentral
Wang H, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017;108(7):1458–68. https://doi.org/10.1111/cas.13253.CrossRefPubMedPubMedCentral
52.
go back to reference Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929–35. https://doi.org/10.1007/s40265-021-01614-x.CrossRefPubMed
Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929–35. https://doi.org/10.1007/s40265-021-01614-x.CrossRefPubMed
53.
go back to reference Peng Z, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173–82. https://doi.org/10.1002/cac2.12214.CrossRefPubMed
Peng Z, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173–82. https://doi.org/10.1002/cac2.12214.CrossRefPubMed
54.
go back to reference Zong HF, et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol Sin. 2024. https://doi.org/10.1038/s41401-024-01279-8.CrossRefPubMed
Zong HF, et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol Sin. 2024. https://doi.org/10.1038/s41401-024-01279-8.CrossRefPubMed
55.
go back to reference Meric-Bernstam F, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558–70. https://doi.org/10.1016/s1470-2045(22)00621-0.CrossRefPubMed
Meric-Bernstam F, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558–70. https://doi.org/10.1016/s1470-2045(22)00621-0.CrossRefPubMed
56.
go back to reference DiPeri TP, et al. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024;14(5):828–45. https://doi.org/10.1158/2159-8290.Cd-23-0838.CrossRefPubMedPubMedCentral
DiPeri TP, et al. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024;14(5):828–45. https://doi.org/10.1158/2159-8290.Cd-23-0838.CrossRefPubMedPubMedCentral
57.
go back to reference Harding JJ, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772–82. https://doi.org/10.1016/s1470-2045(23)00242-5.CrossRefPubMed
Harding JJ, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772–82. https://doi.org/10.1016/s1470-2045(23)00242-5.CrossRefPubMed
58.
go back to reference Xu J, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur J Cancer. 2023;178:1–12. https://doi.org/10.1016/j.ejca.2022.10.004.CrossRefPubMed
Xu J, et al. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. Eur J Cancer. 2023;178:1–12. https://doi.org/10.1016/j.ejca.2022.10.004.CrossRefPubMed
59.
go back to reference Huang S, et al. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018;10(6):864-875. https://doi.org/10.1080/19420862.2018.1486946.
Huang S, et al. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. MAbs. 2018;10(6):864-875. https://doi.org/10.1080/19420862.2018.1486946.
60.
go back to reference Tabernero J, et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29):3255–66. https://doi.org/10.2217/fon-2022-0595.CrossRefPubMed
Tabernero J, et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29):3255–66. https://doi.org/10.2217/fon-2022-0595.CrossRefPubMed
61.
go back to reference Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410. https://doi.org/10.1080/19420862.2022.2153410.
Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023;15(1):2153410. https://doi.org/10.1080/19420862.2022.2153410.
62.
go back to reference Haense N, et al. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420. https://doi.org/10.1186/s12885-016-2449-0.CrossRefPubMedPubMedCentral
Haense N, et al. A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer. 2016;16:420. https://doi.org/10.1186/s12885-016-2449-0.CrossRefPubMedPubMedCentral
63.
go back to reference Jäger M, et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69(10):4270–6. https://doi.org/10.1158/0008-5472.Can-08-2861.CrossRefPubMed
Jäger M, et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69(10):4270–6. https://doi.org/10.1158/0008-5472.Can-08-2861.CrossRefPubMed
64.
go back to reference Pegram MD, et al. First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021;20(8):1442–53. https://doi.org/10.1158/1535-7163.Mct-20-0014.CrossRefPubMedPubMedCentral
Pegram MD, et al. First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021;20(8):1442–53. https://doi.org/10.1158/1535-7163.Mct-20-0014.CrossRefPubMedPubMedCentral
65.
go back to reference Park JJ, et al. Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. 2024;42(16_suppl):3038-3038. https://doi.org/10.1200/JCO.2024.42.16_suppl.3038.
Park JJ, et al. Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study. 2024;42(16_suppl):3038-3038. https://doi.org/10.1200/JCO.2024.42.16_suppl.3038.
66.
go back to reference Gu Y, et al. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024;14(5):1965–86. https://doi.org/10.1016/j.apsb.2024.01.009.CrossRefPubMedPubMedCentral
Gu Y, et al. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024;14(5):1965–86. https://doi.org/10.1016/j.apsb.2024.01.009.CrossRefPubMedPubMedCentral
67.
go back to reference Zhuang W, et al. Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor. Int J Mol Sci. 2023;24(22). https://doi.org/10.3390/ijms242216056.
Zhuang W, et al. Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor. Int J Mol Sci. 2023;24(22). https://doi.org/10.3390/ijms242216056.
68.
go back to reference Pivot X, et al. Milestones over the development of SB3, a trastuzumab biosimilar. Future Oncol. 2018;14(27):2795–803. https://doi.org/10.2217/fon-2018-0270.CrossRefPubMed
Pivot X, et al. Milestones over the development of SB3, a trastuzumab biosimilar. Future Oncol. 2018;14(27):2795–803. https://doi.org/10.2217/fon-2018-0270.CrossRefPubMed
69.
go back to reference Paik J. PF-05280014: A Trastuzumab Biosimilar. BioDrugs. 2018;32(5):515–8. https://doi.org/10.1007/s40259-018-0308-z.CrossRefPubMed
Paik J. PF-05280014: A Trastuzumab Biosimilar. BioDrugs. 2018;32(5):515–8. https://doi.org/10.1007/s40259-018-0308-z.CrossRefPubMed
70.
go back to reference Dhillon S. ABP 980: A Trastuzumab Biosimilar. BioDrugs. 2018;32(5):511–4. https://doi.org/10.1007/s40259-018-0305-2.CrossRefPubMed
Dhillon S. ABP 980: A Trastuzumab Biosimilar. BioDrugs. 2018;32(5):511–4. https://doi.org/10.1007/s40259-018-0305-2.CrossRefPubMed
71.
go back to reference Fu C, et al. Clinical development of CT-P6 in HER2 positive breast cancer. Expert Opin Biol Ther. 2019;19(10):987–92. https://doi.org/10.1080/14712598.2019.1665019.CrossRefPubMed
Fu C, et al. Clinical development of CT-P6 in HER2 positive breast cancer. Expert Opin Biol Ther. 2019;19(10):987–92. https://doi.org/10.1080/14712598.2019.1665019.CrossRefPubMed
72.
go back to reference Audran R, et al. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study. Sci Rep. 2024;14(1):12872. https://doi.org/10.1038/s41598-024-61265-2.CrossRefPubMedPubMedCentral
Audran R, et al. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study. Sci Rep. 2024;14(1):12872. https://doi.org/10.1038/s41598-024-61265-2.CrossRefPubMedPubMedCentral
73.
go back to reference Miller EM, et al. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther Adv Med Oncol. 2019;11:1758835919887044. https://doi.org/10.1177/1758835919887044.CrossRefPubMedPubMedCentral
Miller EM, et al. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther Adv Med Oncol. 2019;11:1758835919887044. https://doi.org/10.1177/1758835919887044.CrossRefPubMedPubMedCentral
74.
go back to reference Allahyari A, et al. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer. 2022;22(1):960. https://doi.org/10.1186/s12885-022-09895-5.CrossRefPubMedPubMedCentral
Allahyari A, et al. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial. BMC Cancer. 2022;22(1):960. https://doi.org/10.1186/s12885-022-09895-5.CrossRefPubMedPubMedCentral
75.
go back to reference Yang J, et al. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. BioDrugs. 2022;36(3):393–409. https://doi.org/10.1007/s40259-022-00534-w.CrossRefPubMedPubMedCentral
Yang J, et al. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. BioDrugs. 2022;36(3):393–409. https://doi.org/10.1007/s40259-022-00534-w.CrossRefPubMedPubMedCentral
76.
go back to reference Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28(4):855–61. https://doi.org/10.1093/annonc/mdx002.CrossRefPubMedPubMedCentral
Bang YJ, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28(4):855–61. https://doi.org/10.1093/annonc/mdx002.CrossRefPubMedPubMedCentral
77.
go back to reference Markham A. Margetuximab: First Approval. Drugs. 2021;81(5):599–604. https://doi.org/10.1007/s40265-021-01485-2.CrossRefPubMed
Markham A. Margetuximab: First Approval. Drugs. 2021;81(5):599–604. https://doi.org/10.1007/s40265-021-01485-2.CrossRefPubMed
78.
go back to reference Catenacci DVT, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022;7(5):100563. https://doi.org/10.1016/j.esmoop.2022.100563.CrossRefPubMedPubMedCentral
Catenacci DVT, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open. 2022;7(5):100563. https://doi.org/10.1016/j.esmoop.2022.100563.CrossRefPubMedPubMedCentral
79.
go back to reference Catenacci DVT, et al. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). 2019;37(4_suppl):65-65. https://doi.org/10.1200/JCO.2019.37.4_suppl.65.
Catenacci DVT, et al. Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC). 2019;37(4_suppl):65-65. https://doi.org/10.1200/JCO.2019.37.4_suppl.65.
80.
go back to reference von Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122–31. https://doi.org/10.1056/NEJMoa1703643.CrossRef
von Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122–31. https://doi.org/10.1056/NEJMoa1703643.CrossRef
81.
go back to reference Tabernero J, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–84. https://doi.org/10.1016/s1470-2045(18)30481-9.CrossRefPubMed
Tabernero J, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–84. https://doi.org/10.1016/s1470-2045(18)30481-9.CrossRefPubMed
82.
go back to reference Liu T, et al. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond). 2019;39(1):38. https://doi.org/10.1186/s40880-019-0384-6.CrossRefPubMed
Liu T, et al. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond). 2019;39(1):38. https://doi.org/10.1186/s40880-019-0384-6.CrossRefPubMed
83.
go back to reference Tabernero J, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26(1):123–31. https://doi.org/10.1007/s10120-022-01335-4.CrossRefPubMed
Tabernero J, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26(1):123–31. https://doi.org/10.1007/s10120-022-01335-4.CrossRefPubMed
84.
go back to reference Wagner AD, et al. EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results. 2025;43(4_suppl):LBA331-LBA331. https://doi.org/10.1200/JCO.2025.43.4_suppl.LBA331.
Wagner AD, et al. EORTC-1203 GITC "INNOVATION": Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy of HER-2 positive stomach cancer: Overall survival results. 2025;43(4_suppl):LBA331-LBA331. https://doi.org/10.1200/JCO.2025.43.4_suppl.LBA331.
85.
go back to reference Hofheinz RD, et al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022;40(32):3750–61. https://doi.org/10.1200/jco.22.00380.CrossRefPubMed
Hofheinz RD, et al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022;40(32):3750–61. https://doi.org/10.1200/jco.22.00380.CrossRefPubMed
86.
go back to reference Zhu X, et al. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. Invest New Drugs. 2023;41(3):473–82. https://doi.org/10.1007/s10637-023-01338-7.CrossRefPubMed
Zhu X, et al. HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial. Invest New Drugs. 2023;41(3):473–82. https://doi.org/10.1007/s10637-023-01338-7.CrossRefPubMed
87.
go back to reference Wei R, et al. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer. J Transl Med. 2024;22(1):641. https://doi.org/10.1186/s12967-024-05453-8.CrossRefPubMedPubMedCentral
Wei R, et al. Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer. J Transl Med. 2024;22(1):641. https://doi.org/10.1186/s12967-024-05453-8.CrossRefPubMedPubMedCentral
88.
go back to reference Pereira PMR, et al. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun. 2022;13(1):2526. https://doi.org/10.1038/s41467-022-30142-9.CrossRefPubMedPubMedCentral
Pereira PMR, et al. Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer. Nat Commun. 2022;13(1):2526. https://doi.org/10.1038/s41467-022-30142-9.CrossRefPubMedPubMedCentral
89.
go back to reference Pereira PMR, et al. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun. 2018;9(1):5137. https://doi.org/10.1038/s41467-018-07608-w.CrossRefPubMedPubMedCentral
Pereira PMR, et al. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun. 2018;9(1):5137. https://doi.org/10.1038/s41467-018-07608-w.CrossRefPubMedPubMedCentral
90.
go back to reference Rao Y, et al. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proc Natl Acad Sci U S A. 2023;120(14):e2220413120. https://doi.org/10.1073/pnas.2220413120.CrossRefPubMedPubMedCentral
Rao Y, et al. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. Proc Natl Acad Sci U S A. 2023;120(14):e2220413120. https://doi.org/10.1073/pnas.2220413120.CrossRefPubMedPubMedCentral
91.
go back to reference Wang J, et al. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer Res. 2022;82(8):1503–17. https://doi.org/10.1158/0008-5472.Can-21-1820.CrossRefPubMedPubMedCentral
Wang J, et al. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. Cancer Res. 2022;82(8):1503–17. https://doi.org/10.1158/0008-5472.Can-21-1820.CrossRefPubMedPubMedCentral
92.
go back to reference Wang S, et al. Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment. Front Oncol. 2023;13:1240676. https://doi.org/10.3389/fonc.2023.1240676.CrossRefPubMedPubMedCentral
Wang S, et al. Circadian rhythm as a key player in cancer progression as well as a therapeutic target in HER2-positive advanced gastric cancer treatment. Front Oncol. 2023;13:1240676. https://doi.org/10.3389/fonc.2023.1240676.CrossRefPubMedPubMedCentral
93.
go back to reference Rocca A, et al. Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. Ther Adv Med Oncol. 2021;13:1758835920985632. https://doi.org/10.1177/1758835920985632.CrossRefPubMedPubMedCentral
Rocca A, et al. Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. Ther Adv Med Oncol. 2021;13:1758835920985632. https://doi.org/10.1177/1758835920985632.CrossRefPubMedPubMedCentral
94.
go back to reference Kolbe K, et al. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol. 2023;149(3):1319–29. https://doi.org/10.1007/s00432-022-04208-6.CrossRefPubMed
Kolbe K, et al. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. J Cancer Res Clin Oncol. 2023;149(3):1319–29. https://doi.org/10.1007/s00432-022-04208-6.CrossRefPubMed
95.
go back to reference Huang D, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS ONE. 2013;8(11): e80290. https://doi.org/10.1371/journal.pone.0080290.CrossRefPubMedPubMedCentral
Huang D, et al. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study. PLoS ONE. 2013;8(11): e80290. https://doi.org/10.1371/journal.pone.0080290.CrossRefPubMedPubMedCentral
96.
go back to reference Grenda A, et al. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery. BMC Gastroenterol. 2020;20(1):382. https://doi.org/10.1186/s12876-020-01531-5.CrossRefPubMedPubMedCentral
Grenda A, et al. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery. BMC Gastroenterol. 2020;20(1):382. https://doi.org/10.1186/s12876-020-01531-5.CrossRefPubMedPubMedCentral
97.
go back to reference Tominaga N, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19(2):553–60. https://doi.org/10.1007/s10120-015-0502-3.CrossRefPubMed
Tominaga N, et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016;19(2):553–60. https://doi.org/10.1007/s10120-015-0502-3.CrossRefPubMed
98.
go back to reference Gullo I, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open. 2015;3(2):E165–70. https://doi.org/10.1055/s-0034-1391359.CrossRefPubMedPubMedCentral
Gullo I, et al. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. Endosc Int Open. 2015;3(2):E165–70. https://doi.org/10.1055/s-0034-1391359.CrossRefPubMedPubMedCentral
99.
go back to reference Xu C, et al. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagn Pathol. 2022;17(1):54. https://doi.org/10.1186/s13000-022-01230-7.CrossRefPubMedPubMedCentral
Xu C, et al. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagn Pathol. 2022;17(1):54. https://doi.org/10.1186/s13000-022-01230-7.CrossRefPubMedPubMedCentral
100.
go back to reference Fan XS, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23. https://doi.org/10.3748/wjg.v19.i21.3316.CrossRefPubMedPubMedCentral
Fan XS, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23. https://doi.org/10.3748/wjg.v19.i21.3316.CrossRefPubMedPubMedCentral
101.
go back to reference Pyo JS, et al. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Markers. 2016;31(1):e1-10. https://doi.org/10.5301/jbm.5000171.CrossRefPubMed
Pyo JS, et al. Concordance rate between HER2 immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis. Int J Biol Markers. 2016;31(1):e1-10. https://doi.org/10.5301/jbm.5000171.CrossRefPubMed
102.
go back to reference Staněk L, et al. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. Mol Med Rep. 2014;10(5):2669–74. https://doi.org/10.3892/mmr.2014.2530.CrossRefPubMed
Staněk L, et al. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. Mol Med Rep. 2014;10(5):2669–74. https://doi.org/10.3892/mmr.2014.2530.CrossRefPubMed
103.
go back to reference Yamashita-Kashima Y, et al. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer. 2014;17(4):638–47. https://doi.org/10.1007/s10120-013-0329-8.CrossRefPubMedPubMedCentral
Yamashita-Kashima Y, et al. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer. 2014;17(4):638–47. https://doi.org/10.1007/s10120-013-0329-8.CrossRefPubMedPubMedCentral
104.
go back to reference Gündisch S, et al. Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Lab Invest. 2015;95(5):561–71. https://doi.org/10.1038/labinvest.2015.37.CrossRefPubMedPubMedCentral
Gündisch S, et al. Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Lab Invest. 2015;95(5):561–71. https://doi.org/10.1038/labinvest.2015.37.CrossRefPubMedPubMedCentral
105.
go back to reference Ge X, et al. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol. 2015;46(6):850–7. https://doi.org/10.1016/j.humpath.2015.02.011.CrossRefPubMed
Ge X, et al. Clinical significance of assessing Her2/neu expression in gastric cancer with dual tumor tissue paraffin blocks. Hum Pathol. 2015;46(6):850–7. https://doi.org/10.1016/j.humpath.2015.02.011.CrossRefPubMed
106.
go back to reference Hofmann M, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.CrossRefPubMed
Hofmann M, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.CrossRefPubMed
107.
go back to reference Radu OM, et al. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol. 2012;137(4):583–94. https://doi.org/10.1309/ajcpxqvs6yghpdcy.CrossRefPubMed
Radu OM, et al. HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol. 2012;137(4):583–94. https://doi.org/10.1309/ajcpxqvs6yghpdcy.CrossRefPubMed
108.
go back to reference Tobias J, et al. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion. Int J Mol Sci. 2023;25(1). https://doi.org/10.3390/ijms25010287.
Tobias J, et al. Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion. Int J Mol Sci. 2023;25(1). https://doi.org/10.3390/ijms25010287.
109.
go back to reference Kasper S, et al. Targeted therapies in gastroesophageal cancer. Eur J Cancer. 2014;50(7):1247–58. https://doi.org/10.1016/j.ejca.2014.01.009.CrossRefPubMed
Kasper S, et al. Targeted therapies in gastroesophageal cancer. Eur J Cancer. 2014;50(7):1247–58. https://doi.org/10.1016/j.ejca.2014.01.009.CrossRefPubMed
110.
go back to reference Endo S, et al. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. Anticancer Res. 2019;39(2):1059–65. https://doi.org/10.21873/anticanres.13213.CrossRefPubMed
Endo S, et al. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202. Anticancer Res. 2019;39(2):1059–65. https://doi.org/10.21873/anticanres.13213.CrossRefPubMed
111.
go back to reference Rivera F, et al. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019;83(6):1175–81. https://doi.org/10.1007/s00280-019-03820-7.CrossRefPubMedPubMedCentral
Rivera F, et al. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019;83(6):1175–81. https://doi.org/10.1007/s00280-019-03820-7.CrossRefPubMedPubMedCentral
112.
go back to reference Abali H, et al. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study. Am J Clin Oncol. 2021;44(7):301–7. https://doi.org/10.1097/coc.0000000000000825.CrossRefPubMed
Abali H, et al. A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study): A Turkish Oncology Group Study. Am J Clin Oncol. 2021;44(7):301–7. https://doi.org/10.1097/coc.0000000000000825.CrossRefPubMed
113.
go back to reference Mondaca S, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer. 2019;22(2):355–62. https://doi.org/10.1007/s10120-018-0861-7.CrossRefPubMed
Mondaca S, et al. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer. 2019;22(2):355–62. https://doi.org/10.1007/s10120-018-0861-7.CrossRefPubMed
114.
go back to reference Pirrelli M, et al. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58(2):397–404. https://doi.org/10.1007/s10620-012-2357-3.CrossRefPubMed
Pirrelli M, et al. Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci. 2013;58(2):397–404. https://doi.org/10.1007/s10620-012-2357-3.CrossRefPubMed
115.
go back to reference Watson S, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol. 2013;24(12):3035–9. https://doi.org/10.1093/annonc/mdt393.CrossRefPubMed
Watson S, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol. 2013;24(12):3035–9. https://doi.org/10.1093/annonc/mdt393.CrossRefPubMed
116.
go back to reference Yoshida H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465(2):145–54. https://doi.org/10.1007/s00428-014-1597-3.CrossRefPubMed
Yoshida H, et al. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465(2):145–54. https://doi.org/10.1007/s00428-014-1597-3.CrossRefPubMed
117.
go back to reference Nergiz D, et al. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma. Indian J Pathol Microbiol. 2022;65(2):321–7. https://doi.org/10.4103/ijpm.Ijpm_535_20.CrossRefPubMed
Nergiz D, et al. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma. Indian J Pathol Microbiol. 2022;65(2):321–7. https://doi.org/10.4103/ijpm.Ijpm_535_20.CrossRefPubMed
118.
go back to reference Fazlollahi L, et al. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. Arch Pathol Lab Med. 2018;142(4):516–22. https://doi.org/10.5858/arpa.2017-0039-OA.CrossRefPubMed
Fazlollahi L, et al. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. Arch Pathol Lab Med. 2018;142(4):516–22. https://doi.org/10.5858/arpa.2017-0039-OA.CrossRefPubMed
119.
go back to reference Huang SC, et al. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer. 2016;19(1):176–82. https://doi.org/10.1007/s10120-014-0453-0.CrossRefPubMed
Huang SC, et al. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance. Gastric Cancer. 2016;19(1):176–82. https://doi.org/10.1007/s10120-014-0453-0.CrossRefPubMed
120.
go back to reference Lee S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59(5):832–40. https://doi.org/10.1111/j.1365-2559.2011.04017.x.CrossRefPubMed
Lee S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59(5):832–40. https://doi.org/10.1111/j.1365-2559.2011.04017.x.CrossRefPubMed
121.
go back to reference Grillo F, et al. The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol. 2013;6(1):10–6. https://doi.org/10.1593/tlo.12334.CrossRefPubMedPubMedCentral
Grillo F, et al. The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol. 2013;6(1):10–6. https://doi.org/10.1593/tlo.12334.CrossRefPubMedPubMedCentral
122.
go back to reference Qiu MZ, et al. Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. J Cancer. 2017;8(17):3531–7. https://doi.org/10.7150/jca.19984.CrossRefPubMedPubMedCentral
Qiu MZ, et al. Comparison of HER2 and Lauren Classification between Biopsy and Surgical Resection Samples, Primary and Metastatic Samples of Gastric Cancer. J Cancer. 2017;8(17):3531–7. https://doi.org/10.7150/jca.19984.CrossRefPubMedPubMedCentral
Metadata
- Title
- Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients
- Authors
-
Lijuan He
Ben Liu
Zhuanfang Wang
Qinying Han
Hao Chen
- Publication date
- 08-03-2025
- Publisher
- Springer US
- Published in
-
Current Treatment Options in Oncology
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277 - DOI
- https://doi.org/10.1007/s11864-025-01300-0
Image Credits
DNA molecule in capsule/© 4designersart / stock.adobe.com, Aplastic Anemia/© Springer Healthcare IME, CAR T-cell attacking cancer cells/© Springer Medicine, June 2024, under a creative commons [CCBY] license.